ArticleTranslational lung cancer research2024
Clinical, pathological, and computed tomography morphological features of lung cancer with spread through air spaces.
Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The clinicoradiological and pathological-molecular characteristics associated with spread through air spaces in stage IA invasive lung adenocarcinoma.Insights into imaging · 2026Article
- Risk factors for pathological invasiveness of non-mucinous invasive pulmonary adenocarcinoma with a maximum diameter of less than or equal to 3 cm in thin-section CT: a retrospective study.Scientific reports · 2026Article
- Imaging advances of predicting spread through air spaces (STAS) in lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Development of a machine learning model for preoperative prediction of spread through air spaces in resectable non-small cell lung cancer: A single-center retrospective study.Oncology letters · 2026Article
- Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety.Frontiers in immunology · 2026Article
- Article
- Which descriptor should spread through air spaces (STAS) be incorporated into? T descriptor versus residual tumor classification.The journal of pathology. Clinical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spread through air spaces (STAS) is significantly associated with decreased overall survival (OS) and reduced recurrence-free survival. However, there are no reliable methods to confirm the presence of STAS before surgery. The sensitivity and specificity of the intraoperative frozen section diagnosis of STAS are not satisfactory. This study sought to determine the clinical, pathological, and computed tomography (CT) features of lung cancer with STAS before surgery to guide treatment decisions. Methods: The data of 121 patients who were positive for STAS and 121 who were negative for STAS as confirmed by surgery and pathology were collected at Jiangsu Cancer Hospital from January 2020 to December 2022. The differences between the two groups in terms of the clinical, pathological, and CT characteristics were compared. Results: STAS occurred not only in lung adenocarcinoma (LUAD) (106 of 121, 87.6%), but also in other pathological types of lung cancer (15 of 121, 12.4%). STAS was significantly correlated with pathological invasiveness [pathological differentiation, tumor, node, metastasis (TNM) staging, vascular invasion, and pleural invasion; all P<0.05]. STAS was most common in solid tumors (95 of 121, 78.51%). The receiver operating characteristic (ROC) curve showed that the optimal cut-off value for diagnosing STAS based on diameter is 1.55 cm with a sensitivity of 73.3% and a specificity of 47.9%. The percentage of solid components (PSC) is an independent influencing factor of lung cancer with STAS [odds ratio (OR) =111.27; P<0.05] with an optimal cut-off value of 63%, a sensitivity of 92.5%, and a specificity of 72.7%. In the part-solid nodules, the occurrence rate of STAS increased as the PSC increased. STAS was only observed in part-solid nodules with a PSC greater than 25%. Among the CT morphological features, lobulation was an independent influencing factor of lung cancer with STAS (OR =3.513; P<0.05), and persistent indistinct margin ground-glass opacity around the primary lesion of lung cancer (21 of 121, 17.36%) and satellite foci (9 of 121, 7.44%) strongly indicated the existence of STAS. Conclusions: The clinical, pathological and CT features of STAS may guide clinicians to develop appropriate strategies and improve the survival rate of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.